NCT04999592View on ClinicalTrials.gov

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

PHASE2TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

March 1, 2024

Study Completion Date

November 1, 2024

Conditions
Out-Of-Hospital Cardiac ArrestPneumonia
Interventions
DRUG

Standard of care without prophylaxis

Administer antibiotics in response to infection

DRUG

Antibiotic prophylaxis

Ceftriaxone 2 gm IV q12h for 3 days

Trial Locations (1)

04102

Maine Medical Center, Portland

Sponsors

Collaborators (1)

MaineHealth
All Listed Sponsors
collaborator

MaineHealth

OTHER

collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

collaborator

University of New England

OTHER

lead

David J. Gagnon

OTHER

NCT04999592 - Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT) | Biotech Hunter | Biotech Hunter